Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Q2 Revenues Improve 4 Percent; Firm Adjusts 2013 EPS Guidance

NEW YORK (GenomeWeb News) – Revenues for Laboratory Corporation of America's second quarter rose almost 4 percent year over year, it reported today.

Total revenues reached $1.47 billion for the three months ended June 30, up from $1.42 billion a year ago, and edging out the average Wall Street estimate of $1.46 billion.

Testing volume, measured by requisitions, increased 5 percent, while revenue per requisition declined 2 percent due to a reduction in Medicare payments, delays and denials of coverage for existing tests by some payors after implementation of recently adopted molecular pathology codes, and sequestration. LabCorp also said its drugs of abuse testing saw "strong growth."

The company recorded a profit of $152.3 million, or $1.62 per share, in the quarter, compared to $153.8 million, or $1.56 per share, a year ago. On an adjusted basis, EPS was $1.80, matching the consensus Wall Street estimate.

During the quarter, LabCorp took a restructuring charge of $6.6 million, compared to $3.4 million a year ago. Its SG&A expenses inched up a fraction of 1 percent to $280.9 million from $279.5 million in the year-ago period.

LabCorp repurchased $362 million of stock, or about 3.7 million shares, in the second quarter, and as of June 30, $592.1 million of repurchase authorization remained under its previously approved buyback plan.

The Burlington NC-based company ended the quarter with $111.3 million in cash and short-term investments, it said.

LabCorp also updated its guidance for full-year 2013. It reiterated an earlier forecast of revenue growth of between 2 and 3 percent, but changed its adjusted EPS guidance. EPS, excluding amortization, is now expected to be in the range of $6.90 to $7.10, compared to an earlier guidance of $6.85 to $7.15. The new range includes the negative impact of about $.35 from Medicare payment reductions, but excludes any impact from share buybacks after June 30.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.